Viking Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Viking Therapeutics es Brian Lian , nombrado en Sep 2012, tiene una permanencia de 12.17 años. compensación anual total es $12.63M, compuesta por 4.9% salario y 95.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.71% de las acciones de la empresa, por valor de $100.41M. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 10.5 años, respectivamente.
Información clave
Brian Lian
Chief Executive Officer (CEO)
US$12.6m
Compensación total
| Porcentaje del salario del CEO | 4.9% |
| Permanencia del CEO | 12.2yrs |
| Participación del CEO | 1.7% |
| Permanencia media de la dirección | 5.3yrs |
| Promedio de permanencia en la Junta Directiva | 10.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Nov 04Viking Therapeutics: Lots Of Positives
Oct 28Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Sep 25Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Aug 30Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
Jul 25We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Viking Therapeutics: Playing Second Fiddle To Madrigal
Aug 30We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Jul 13Revisiting Viking Therapeutics
Apr 20We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Apr 12We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Dec 17Viking Therapeutics: Remaining Bullish And Sticking To My Plan
Aug 27Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder
Jun 17Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?
Jan 13Viking Therapeutics announces senior management appointments
Jan 06Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Dec 09
Viking Therapeutics: Progressing Steadily, But Concerns Remain
Nov 29Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$99m |
| Jun 30 2024 | n/a | n/a | -US$97m |
| Mar 31 2024 | n/a | n/a | -US$94m |
| Dec 31 2023 | US$13m | US$615k | -US$86m |
| Sep 30 2023 | n/a | n/a | -US$81m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$72m |
| Dec 31 2022 | US$5m | US$612k | -US$69m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$59m |
| Mar 31 2022 | n/a | n/a | -US$57m |
| Dec 31 2021 | US$4m | US$594k | -US$55m |
| Sep 30 2021 | n/a | n/a | -US$54m |
| Jun 30 2021 | n/a | n/a | -US$50m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$5m | US$577k | -US$39m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$32m |
| Mar 31 2020 | n/a | n/a | -US$31m |
| Dec 31 2019 | US$4m | US$525k | -US$26m |
| Sep 30 2019 | n/a | n/a | -US$24m |
| Jun 30 2019 | n/a | n/a | -US$24m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$1m | US$485k | -US$22m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$20m |
| Mar 31 2018 | n/a | n/a | -US$19m |
| Dec 31 2017 | US$805k | US$440k | -US$21m |
Compensación vs. Mercado: La compensación total de Brian($USD12.63M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD7.74M).
Compensación vs. Ingresos: La compensación de Brian ha aumentado mientras la empresa no es rentable.
CEO
Brian Lian (58 yo)
12.2yrs
Permanencia
US$12,628,061
Compensación
Dr. Brian Lian, Ph D., served as Director at Apricus Biosciences, Inc. He has been the Chief Executive Officer and President at Viking Therapeutics, Inc. since September 24, 2012. Dr. Lian has been an Inde...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 12.2yrs | US$12.63m | 1.71% $ 100.4m | |
| Chief Financial Officer | 5.3yrs | US$3.50m | 0.0010% $ 60.4k | |
| Chief Operating Officer | 3.8yrs | US$3.51m | 0.18% $ 10.8m | |
| Vice President of Finance & Administration | 6.6yrs | US$619.56k | sin datos | |
| Senior Vice President of Pharmaceutical Development | 1.8yrs | sin datos | sin datos |
5.3yrs
Permanencia media
58.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de VKTX es experimentado (5.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 12.2yrs | US$12.63m | 1.71% $ 100.4m | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Independent Director | 10.5yrs | US$169.37k | 0.10% $ 5.9m | |
| Independent Director | 10.5yrs | US$192.77k | 0.0085% $ 499.9k | |
| Independent Director | 7.3yrs | US$189.62k | 0.027% $ 1.6m | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Independent Chairman | 10.5yrs | US$222.72k | 0.043% $ 2.5m | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Independent Director | 5.3yrs | US$178.65k | 0% $ 0 |
10.5yrs
Permanencia media
63.5yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de VKTX son experimentados ( 10.5 años antigüedad media).